IDEXX Laboratories Reports 10% Revenue Growth but Lowers Operating Margin Outlook
IDEXX Laboratories (IDXX) reported third-quarter revenue of approximately $1.21 billion, a 10% increase year-over-year, driven largely by an 11% rise in recurring diagnostics sales to veterinary professionals. While diluted earnings per share grew 18% to $4.01, the company's decision to trim its full-year operating margin outlook suggests that recent profit gains are being driven by non-operational factors such as lower tax rates, reduced interest expenses, and share buybacks rather than increased testing demand. The market reacted positively with shares rising roughly 16% in early trading. However, analysts note that the lowered margin guidance implies a stagnant fourth quarter as the company absorbs costs related to its CoVet software deal. Investors are closely monitoring rapid assay product volumes and whether future growth can be sustained through testing demand rather than just pricing adjustments.
Tickers: $IDXX
Topics: diagnostics sales operating margin profit forecast revenue growth